ITFI20050246A1 - Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma - Google Patents

Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma

Info

Publication number
ITFI20050246A1
ITFI20050246A1 IT000246A ITFI20050246A ITFI20050246A1 IT FI20050246 A1 ITFI20050246 A1 IT FI20050246A1 IT 000246 A IT000246 A IT 000246A IT FI20050246 A ITFI20050246 A IT FI20050246A IT FI20050246 A1 ITFI20050246 A1 IT FI20050246A1
Authority
IT
Italy
Prior art keywords
camptotecin
melanoma
derivative
preparation
treatment
Prior art date
Application number
IT000246A
Other languages
English (en)
Inventor
Mario Bigioni
Monica Binaschi
Original Assignee
Menarini Internat Operations Luxembourg Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Internat Operations Luxembourg Sa filed Critical Menarini Internat Operations Luxembourg Sa
Priority to IT000246A priority Critical patent/ITFI20050246A1/it
Priority to PCT/EP2006/069182 priority patent/WO2007063124A1/en
Priority to ARP060105319A priority patent/AR057958A1/es
Priority to TW095144607A priority patent/TW200731989A/zh
Publication of ITFI20050246A1 publication Critical patent/ITFI20050246A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IT000246A 2005-12-02 2005-12-02 Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma ITFI20050246A1 (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT000246A ITFI20050246A1 (it) 2005-12-02 2005-12-02 Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma
PCT/EP2006/069182 WO2007063124A1 (en) 2005-12-02 2006-12-01 Use of a compound comprising a camptothecin derivative for preparing pharmaceutical formulations useful in the treatment of melanoma
ARP060105319A AR057958A1 (es) 2005-12-02 2006-12-01 Uso de un compuesto que comprende un derivado de la camptotecina para la preparacion de formulaciones farmaceuticas utiles en el tratamiento del melanoma
TW095144607A TW200731989A (en) 2005-12-02 2006-12-01 Use of a compound comprising a camptothecin derivative for preparing pharmaceutical formulations useful in the treatment of melanoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000246A ITFI20050246A1 (it) 2005-12-02 2005-12-02 Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma

Publications (1)

Publication Number Publication Date
ITFI20050246A1 true ITFI20050246A1 (it) 2007-06-03

Family

ID=37771061

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000246A ITFI20050246A1 (it) 2005-12-02 2005-12-02 Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma

Country Status (4)

Country Link
AR (1) AR057958A1 (it)
IT (1) ITFI20050246A1 (it)
TW (1) TW200731989A (it)
WO (1) WO2007063124A1 (it)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives

Also Published As

Publication number Publication date
WO2007063124A1 (en) 2007-06-07
TW200731989A (en) 2007-09-01
AR057958A1 (es) 2007-12-26

Similar Documents

Publication Publication Date Title
NO20075628L (no) Farmasøytiske formuleringer
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
MA28489B1 (fr) Preparations pharmaceutiques
IL191531A0 (en) Orally absorbed pharmaceutical formulation
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
ITMI20042477A1 (it) Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche
ITMI20050261A1 (it) Analoghi strutturali di avenatramidi loro uso in composizioni utili nel trattamento di disordini dermatologici
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
SV2010003753A (es) Dronedarona para la prevencion de la cardioversion
BRPI0517782A (pt) formulações de benzotiazol e uso das mesmas
ITMI20051273A1 (it) Composizioni in forma di lipogel per uso cosmetico detergente e farmaceutico
ITMI20050417A1 (it) Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica
ITPD20060092A1 (it) Prodotto cosmetico o farmaceutico per uso topico
ITFI20050246A1 (it) Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma
HK1092734A1 (en) Oral formulation for twice-daily administration
ITMI20040443A1 (it) Prpcesso per la preparazione di ..15-16-17-cheto-steroidi e loro uso nella sintesi di composti farmacologicamente attivi
ITRM20060440A1 (it) Uso della nifedipina per il trattamento antirughe
ITTO20050234A1 (it) Derivati 4-arilpiperidinici e loro uso per la preparazione di un medicamento per il trattamento di disordini del snc
ITMI20052464A1 (it) Procedimento per la preparazi9one di norelgestromin norelgestromina
ITRM20050391A1 (it) Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
CL2004001607A1 (es) Uso de gabaxafol para preparar un medicamento util en el tratamiento de la depresion.
ITRM20040329A1 (it) Procedimento per la preparazione di un liofilizzato di muscari comosum da utilizzarsi in una composizione farmaceutica per il trattamento della stipsi.
ITBS20040080A1 (it) Prodotto ad uso odontoiatrico
ITMI20050171A1 (it) Preparazione di aldesleuchina per uso farmaceutico
ITNO20050013A1 (it) Utensile per la frantumazione delle compresse medicinali